Zimmer Holdings (NYSE:ZMH) specializes in providing knee and hip replacements to patients across the globe. Close to a decade ago, the business was growing briskly and demographic trends were thought to be on Zimmer's side. The aging of the baby boomers in the United States and older individuals abroad were supposed to power Zimmer well into this century. Unfortunately, the latest recession has slowed Zimmer's prospects and the company has yet to return to its former glory.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers

Recent Results and Outlook
Reported second quarter sales fell 1.1% to $1.1 billion. Backing out negative currency fluctuations, which stemmed from a stronger dollar that reduced reported overseas sales, the top line advanced a more respectable 1.8%. Cost cutting moves (the company is referring to them as "commercial and operational excellence programs") and backing out the foreign exchange changes resulted in recurring profit growth of 10.7% to $235.6 million, or $1.34 per diluted share.

Looking at the major product areas, reported knee and hip replacement sales fell 2% and 1%, respectively. These make up the vast majority of the total company top line. Smaller units, including trauma and surgical, grew 7% each, but were offset by an 8% decline in dental and 7% drop in spine. By region, both the Americas and Asia Pacific regions grew 1%, but were partially offset by a 6% decline in Europe.

For the full year, Zimmer expects modest sales growth between 2.5% and 3.5%, which ignores currency fluctuations. Backing out the fluctuations, reported growth should come in between zero and 1.5%. Earnings expectations are in a range of $5.25 and $5.35 per diluted share on an adjusted basis, and $4.75 to $4.85 on a reported basis.

SEE: A Primer On Currency Regimes

The Bottom Line
Zimmer has continued to struggle to grow since the Great Recession. Its track record over the past decade looks impressive. During this period, average annual sales growth has been above 14% and profits have advanced 18% each year over this time frame. However, this includes the past five years of results that have seen sales growth average less than 5% and earnings grow less than 3.5%.

Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers to returning to robust sales growth. During the earnings conference call, it spoke of solid results in international markets, but Europe has been a real drag and could continue to struggle for some time.

SEE: Great Expectations: Forecasting Sales Growth

On a positive note, the forward earnings multiple of just over 11 leaves room for upside, should growth trends start to perk up. However, rival Stryker (NYSE:SYK) has been able to grow faster in recent years and trades at less than 13 times forward expectations, which is also quite reasonable. Other firms operating in the medical device space, including Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), also trade in the low teens. So do the diversified healthcare giants of Johnson & Johnson (NYSE:JNJ) and Abbott Labs (NYSE:ABT), which also operate sizable medical device units.

Add it up and there are likely better investment candidates than Zimmer in the medical field. Zimmer does again trade at a very reasonable P/E, which leaves room for upside should demand increase. There is also the potential for a buyout from a firm of Abbott or JNJ's size. It might also make sense for Stryker and Zimmer to combine forces and use any merger as an opportunity to cut corporate overhead even further.

At the time of writing, Ryan C. Fuhrmann was long shares of St. Jude but did not own shares in any other company mentioned in this article.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!